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Abstract 1 
 2 
Deficits of brain parvalbumin (PV) are a consistent finding in schizophrenia and 3 
models of psychosis. We investigated whether this is associated with abnormal PV 4 
gene (PVALB) methylation in the brain in schizophrenia. Bisulfite pyrosequencing 5 
was used to determine cytosine (CpG) methylation in a PVALB promoter sequence. 6 
Greater PVALB methylation was found in schizophrenia hippocampus, while no 7 
differences were observed in prefrontal cortex. LINE-1 methylation, a measure of 8 
global methylation, was also elevated in both regions in schizophrenia, although the 9 
PVALB change was independent of this effect. These results provide the first 10 
evidence that PVALB promoter methylation is abnormal in schizophrenia and suggest 11 
that this epigenetic finding may relate to the reduction of PV expression seen in the 12 
disease.  13 
 14 
Keywords: Schizophrenia, parvalbumin, DNA methylation, post-mortem brain, 15 
LINE-1. 16 
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1. Introduction 38 
 39 
It is now well established that there is a dysfunction of GABAergic systems in 40 
the brain in schizophrenia. Early post-mortem studies have shown deficits in 41 
interneurons in the neocortex and hippocampus [1] reflected by lower density of 42 
hippocampal GABA uptake sites [2]. Subsequent confirmation has come from 43 
observations of deficits in the GABAergic marker glutamic acid decarboxylase 44 
(GAD)-1 mRNA and GAD-67 protein throughout the cortex [3]. These deficits 45 
appear to be selective for subtypes of GABAergic neurons, most notably those 46 
containing parvalbumin (PV), immunostaining for which is reduced in frontal cortex 47 
and hippocampus in schizophrenia [4,5]. It seems likely that these deficits contribute 48 
to the cognitive disturbances in schizophrenia [6], although it is conceivable that 49 
hippocampal parvalbumin/GABA deficits may result in dopaminergic hyperfunction 50 
[2] and thereby contribute to positive symptoms. 51 
The pathogenic mechanisms underlying the PV deficit in schizophrenia are 52 
also unclear, although it has been suggested that the GABAergic cells are intact but 53 
hypofunctioning [7]. This is consistent with the fact that the PV deficit in certain 54 
animal models of the disease appears to be related to a reversible effect of oxidative 55 
stress [8]. We have speculated whether the PV deficit might relate to epigenetic 56 
changes that could be induced by such environmental influences. One epigenetic 57 
factor is that of DNA methylation occurring at cytosine residues in CpG sequences; 58 
within promoter sequences this methylation can have major effects on gene 59 
expression [9]. There is some evidence for dynamic effects on methylation of the PV 60 
gene (PVALB) promoter sequence associated with manganese-induced neurotoxic 61 
damage in the mouse hippocampus [10]; also, we recently found a PVALB 62 
hypermethylation in the hippocampus of rats undergoing subchronic phencyclidine 63 
administration [11], in which a PV immunostaining and mRNA deficits are well-64 
established [12–16]. Additionally, a specific association between elevated PVALB 65 
methylation and methamphetamine (METH)-induced psychosis was reported in 66 
METH-dependent subjects compared to controls with no history of drug abuse or 67 
psychiatric diagnosis [17].  68 
We hypothesise that changes in methylation of the PVALB promoter might 69 
relate to PV deficits in schizophrenia. Thus we have determined the methylation 70 
status of several CpG methylation sites within this sequence in frontal cortical and 71 
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hippocampal tissue taken post-mortem from patients with schizophrenia and control 72 
subjects. The results were compared with a global measure of DNA methylation, that 73 
of LINE-1. 74 
 75 
2. Material and Methods 76 
 77 
2.1. Post-mortem human brain tissue 78 
 A post-mortem brain tissue sample from 15 schizophrenia subjects and 16 79 
age-matched controls was collected at the University of Nottingham; this sample was 80 
previously investigated for glutamatergic and GABAergic markers (e.g. Reynolds et 81 
al., 1990). Tissues were taken and stored at -70°C in compliance with the UK Human 82 
Tissue Act. Details of the sample subjects are provided in Table 1. 83 
 84 
2.2. DNA extraction, Bisulphite Conversion and Pyrosequencing 85 
 Genomic DNA from human samples was extracted from PFC and 86 
hippocampus, using QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA), and was 87 
bisulphite-modified to convert unmethylated cytosine residues to uracil using the 88 
EpiTec Fast DNA Bisulphite Kit (Qiagen) with a calculated mean conversion of 99%. 89 
We identified an equivalent DNA sequence to that chosen previously in an animal 90 
study [11], in the 5’ regions of the human PVALB gene and developed a 91 
pyrosequencing method for determination of methylation at each CpG sites within 92 
this sequence following bisulphite reaction. The sequence was amplified by PCR 93 
using primers, including a biotinylated reverse primer, as follows: 5'-94 
AGTGGAGAGAGAAAGGGAGTA-3' (forward) and 5'-95 
[btn]AACACCAAAAAAAAAACCACCTCTAAAATT-3' (reverse) (Eurofins MWG 96 
Operon).  97 
PyroMark Q24 CpG LINE-1 sequence-based pyrosequencing was used to quantify 98 
methylation at four CpG sites in positions 331 to 318 of LINE-1 (GenBank accession 99 
number X58075) (Qiagen). 100 
  PCR reactions, amplification conditions and the methylation profile were 101 
carried out according to our previous study [11]. The sequencing primer used for 102 
PVALB studies was as follows: 5'- ATTAGTTAAGGTTTTTAGATTTGA -3' 103 
(Eurofins MWG Operon). Pyrosequence setup and data reading were conducted by 104 
PyroMark Q24 2.0.6.20 software (UK). Samples underwent PCR and pyrosequencing 105 
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in duplicate; any inconsistencies between samples were resolved following further 106 
repetition.  107 
 108 
2.3. Statistical Analysis 109 
 Data obtained from the pyrosequencing were compared by unpaired t test and 110 
were considered significantly relevant when p ≤ 0.05. All the analysis was done using 111 
SPSS 20.0 (IBM Corp: Armonk, NY, USA). Variance analysis was used to evaluate 112 
possible associations of age and sex of the patients with the methylation levels found. 113 
 114 
3. Results 115 
 116 
A series of samples of both frontal cortex and hippocampus from 16 control 117 
subjects and 15 schizophrenia subjects (Table 1) successfully underwent bisulphite 118 
conversion, PCR and pyrosequencing to determine methylation in the LINE-1 and 119 
PVALB sequences. All samples demonstrated single PCR bands with no evidence of 120 
DNA degradation. A significant effect of diagnostic category on PVALB methylation 121 
was found in the hippocampus (F=3.465; p=0.021) but not in the frontal cortex 122 
(F=0.715; p=0.591). Figure 1 shows that the effect in the hippocampus reflected 123 
increases in methylation in schizophrenia at CpG2 (F=8.250; p=0.008) and CpG4 124 
(F=12.195; p=0.002). 125 
The mean methylation of LINE-1 was highly significantly increased in both 126 
frontal cortex (t=2.995; p=0.006) and hippocampus (t=2.786; p=0.009) in 127 
schizophrenia (Figure 2). Including the respective LINE-1 methylation results as a 128 
covariate in the PVALB analyses above, there were no qualitative differences in the 129 
statistical results: methylation at CpG2 and CpG4 in the hippocampus remained 130 
significantly elevated in schizophrenia. 131 
Age was significantly different between the two groups but showed no 132 
significant correlation with any methylation measure; including it as a covariate also 133 
had no substantial influence on the results of the analyses above; differences in LINE-134 
1 methylation remained significant as did hippocampal PVALB methylation at CpG2 135 
and CpG4. 136 
 137 
4. Discussion 138 
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 The major findings from our study indicate a specific increase in PVALB 139 
promoter methylation in the hippocampus in schizophrenia which is independent of 140 
increases in a measure of global methylation in the brain.  141 
 To the best of our knowledge, this is the first study reporting hypermethylation 142 
in PVALB promoter in schizophrenia patients; these data are supported by previously 143 
identified evidence suggesting that hyperfunctional DNA methylation may be 144 
responsible for deficiencies in GABAergic neurotransmission [18,19]. As DNA 145 
promoter hypermethylation can contribute to reduced gene expression, we suggest 146 
that the well-established reduction in PV expression in the brain in schizophrenia may 147 
be related to increased methylation of CpG sites within the gene promoter region.  148 
The deficit in PV expression is much greater in the hippocampus [5] than in the cortex 149 
[4], which may relate to the fact that a statistically significant hypermethylation was 150 
only observed in the hippocampus. We have reported elevated methylation of an 151 
equivalent sequence in the PVALB promoter of the hippocampus of rats which have 152 
undergone a sub-chronic phencyclidine (PCP) regime, modelling some symptoms of 153 
schizophrenia [11] and also find an elevation of CpG 2 methylation in blood-derived 154 
DNA in subjects with methamphetamine-induced psychosis [17].  155 
 The PVALB promoter region selected spans many transcription factor (TF) 156 
binding sites including those for paired box domain gene 5 (PAX5) and cyclic AMP-157 
responsive element (CREB). At CpG2 there is a recognition site for PAX5, which has 158 
an important role in regulate the mid-hindbrain organisation during neurodevelopment 159 
[20–22], while at CpG4 is spanned by the binding site for CREB which possesses 160 
intrinsic histone acetyltransferase activity [23,24] important for gene regulation. It has 161 
been demonstrated that methylation can block this binding [25]. Additionally, 162 
genome-wide association studies have demonstrated that this TF is associated with 163 
schizophrenia [26] and interestingly, increases in DNA methylation of the CREB 164 
binding protein gene following clozapine treatment were significantly correlated with 165 
clinical improvements in treatment-resistant schizophrenia [23].  166 
Our results reveal hypermethylation in LINE-1 in brain tissue of schizophrenia 167 
patients compared to controls. These repetitive elements play an important role in 168 
gene expression and may be involved in the regulation of diverse biological 169 
processes, including DNA damage and repair, inflammation, immune function, 170 
embryogenesis, cell differentiation, cell response to external stimuli and hormonal 171 
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responses [27], so epigenetic dysfunction in these elements in the brain might be 172 
involved in neurodegenerative and psychiatric diseases [28].  173 
The increase in LINE-1 methylation indicates that there may be a global 174 
elevation in brain DNA methylation in schizophrenia. It has been reported that in the 175 
brain in schizophrenia there is an upregulation of DNA-methyltransferases (DNMT) 176 
[29,30], so a LINE-1 hypermethylation found in our study could well be a 177 
consequence of this DNMT upregulation. Abnormalities in LINE-1 methylation are 178 
seen in association with early life trauma in schizophrenia [31] and in PTSD [32], 179 
although such studies inevitably rely on blood-derived DNA. 180 
However, we found that the increase in PVALB methylation was unrelated to 181 
the change in LINE-1 methylation, and thus it would appear that the finding in 182 
PVALB is an independent effect, perhaps selective to this gene and potentially related 183 
to the specific deficit in PV in the brain in schizophrenia. It was not possible to 184 
determine PV expression in the samples used in the current study, and thus a direct 185 
assessment of the correlation b tween DNA methylation and gene expression could 186 
not be performed. 187 
This study has some further limitations; the sample size was not large and, as 188 
it is a post-mortem study, the patients were inevitably mostly elderly. There are other 189 
variables associated with post-mortem studies that are difficult to control; these 190 
include the post-mortem interval, although modelling this with rat brains at room 191 
temperature over 96 hours has demonstrated no effect on DNA methylation [33].  192 
Furthermore, the patients were not drug free and, as it is known that antipsychotic 193 
drug administration may have effects on gene methylation [34], we cannot distinguish 194 
relationships with disease from effects of drug treatment.  195 
 196 
5. Conclusions and Future Perspectives 197 
 This is the first evidence for an elevation of DNA methylation in the promoter 198 
sequence of PVALB in schizophrenia, consistent with recent findings in both drug-199 
induced psychosis and in an animal model of the disease. This epigenetic effect may 200 
underlie the PV deficits seen in both the disease and the PCP model. The PVALB 201 
hypermethylation occurs in conjunction with, but independent of, increases in a 202 
measure of global DNA methylation in the brain in schizophrenia. Much more needs 203 
to be investigated in order to determine the effects of PVALB promoter methylation 204 
in schizophrenia and related diseases and animal models. It would be important to 205 
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determine if the hypermethylation seen in these specific CpG sites is directly related 206 
to decreased PV expression in the disease. 207 
 208 
Executive Summary 209 
• A deficit of parvalbumin (PV) expression in GABAergic neurons of the 210 
hippocampus and frontal cortex is a feature common to schizophrenia.  211 
• Increased methylation of the promoter region of the PV gene (PVALB) is 212 
associated with methamphetamine psychosis. 213 
• Equivalent sequence in rat brain DNA also shows increased methylation in the 214 
phencyclidine model of schizophrenia. 215 
• We found greater PVALB promoter DNA methylation in hippocampus of 216 
post-mortem schizophrenia patients compared to control subjects. 217 
• This increase in methylation is specific to a site within a transcription factor 218 
binding sequence. 219 
• We found hypermethylation in LINE-1 in hippocampus and prefrontal cortex 220 
of schizophrenia post-mortem brains. 221 
• The changes in PVALB methylation were independent of those in LINE-1.  222 
• This hypermethylation may, through effects on transcription, contribute to the 223 
enduring reduction in PV in schizophrenia. 224 
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Figure 1. 
 
 
 
Figure 1. Percentage methylation PVALB in the hippocampus and prefrontal cortex 
(PFC) in post mortem brains in schizophrenia and controls of Nottingham Series. 
Values are expressed as the mean ± SEM. (Student’s t test, n = 15 schizophrenia and 
n= 16 controls). **p<0.01. 
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Figure 2. LINE-1 global methylation in the hippocampus and prefrontal cortex (PFC) 
in post mortem brains in schizophrenia and controls of Nottingham Series. Values are 
expressed as the mean ± SEM. (Student’s t test, n = 15 schizophrenia and n= 16 
controls). **p<0.01. 
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Table 1. Description of demographic data of schizophrenia patients and controls  
 Control (n = 16) Schizophrenia (n = 15) P value 
    
Age (Mean ±SD) 67.25 ± 12.73  52.60 ± 18.18  0.016 
    
Men (%) 11 (68%) 11 (73%)  
    
PM Hrs (Mean ±SD) 27.68 ± 11.42 27.08 ± 14.05 0.906 
    
*PM Hrs: Post-mortem interval of collection of the samples in hours 
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